A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Company Overview We are a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Our clinical development strategy is to evaluate our product candidates in rational combinations, where appropriate, and earlier in the course of disease in the adjuvant and neoadjuvant settings, which we believe has the potential to maximize their impact.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 219M | 219M | - | - | 51M | 28M |
| Net Income | -114M | -114M | -274M | -113M | -59M | -50M |
| EPS | $-1.28 | $-1.28 | $-3.36 | $-1.96 | $-1.42 | $-1.41 |
| Free Cash Flow | -73M | -73M | -251M | -118M | -91M | -58M |
| ROIC | -13.4% | -10.9% | -25.9% | -20.7% | -16.8% | -16.5% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.03 | 0.03 | 0.02 | - | 0.01 | 0.02 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -159M | -159M | -327M | -134M | -63M | -50M |
| Operating Margin | -72.8% | -72.8% | - | - | -122.7% | -179.9% |
| ROE | -11.1% | -10.9% | -25.9% | - | -16.8% | -16.5% |
| Shares Outstanding | 89M | 89M | 82M | 58M | 41M | 35M |
| Metric | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 20M | 28M | 51M | N/A | N/A | 219M | 219M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 40M | 58M | 90M | 130M | 295M | 315M | 315M |
| SG&A | 15M | 20M | 24M | 28M | 39M | 63M | 63M |
| EBIT | -35M | -50M | -63M | -134M | -327M | -159M | -159M |
| Op. Margin | -180.9% | -179.9% | -122.7% | N/A | N/A | -72.8% | -72.8% |
| Net Income | -34M | -50M | -59M | -113M | -274M | -114M | -114M |
| Net Margin | -176.6% | -178.1% | -115.2% | N/A | N/A | -52.0% | -52.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||
| ROIC | -17.4% | -16.5% | -16.8% | -20.7% | -25.9% | -10.9% | -13.4% |
| ROE | -17.4% | -16.5% | -16.8% | N/A | -25.9% | -10.9% | -11.1% |
| ROA | -11.6% | -13.0% | -15.1% | -17.4% | -24.4% | -10.2% | -10.2% |
| Cash Flow | |||||||
| Op. Cash Flow | 55M | -56M | -87M | -115M | -248M | -71M | -71M |
| Free Cash Flow | 55M | -58M | -91M | -118M | -251M | -73M | -73M |
| Owner Earnings | 50M | -66M | -101M | -136M | -285M | -120M | -120M |
| CapEx | 493K | 2.6M | 3.4M | 2.4M | 3.9M | 2.4M | 2.4M |
| Maint. CapEx | 1.4M | 1.7M | 2.1M | 2.5M | 2.4M | 2.7M | 2.7M |
| Growth CapEx | 0 | 919K | 1.3M | 0 | 1.5M | 0 | 0 |
| D&A | 1.4M | 1.7M | 2.1M | 2.5M | 2.4M | 2.7M | 2.7M |
| CapEx/OCF | 0.9% | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | 0.0% | 0.0% |
| Stock-Based Comp | 3.6M | 8.2M | 12M | 18M | 35M | 46M | 46M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||
| Net Debt | -277M | -242M | -361M | -522M | -657M | -611M | -85M |
| Cash & Equiv. | 72M | 92M | 69M | 157M | 84M | 113M | 113M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | 28M |
| Debt/Equity | 0.03 | 0.02 | 0.01 | N/A | 0.02 | 0.03 | 0.03 |
| Interest Coverage | -431.0 | -708.0 | -1041.7 | -1948.2 | -13079.0 | N/A | N/A |
| Equity | 198M | 302M | 349M | N/A | 1.1B | 1.0B | 1.0B |
| Total Assets | 298M | 381M | 388M | 649M | 1.1B | 1.1B | 1.1B |
| Total Liabilities | 100M | 80M | 39M | N/A | 65M | 86M | 86M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -127M | -177M | -235M | -348M | -623M | -737M | -737M |
| Working Capital | 250M | 206M | 339M | 506M | 644M | 608M | 608M |
| Current Assets | 289M | 251M | 370M | 533M | 690M | 667M | 667M |
| Current Liabilities | 39M | 45M | 32M | 27M | 46M | 59M | 59M |
| Per Share Data | |||||||
| EPS | -1.40 | -1.41 | -1.42 | -1.96 | -3.36 | -1.28 | -1.28 |
| Owner EPS | 2.05 | -1.86 | -2.44 | -2.36 | -3.49 | -1.35 | -1.35 |
| Book Value | 8.05 | 8.54 | 8.46 | N/A | 12.97 | 11.52 | 11.52 |
| Cash Flow/Share | 2.25 | -1.58 | -2.11 | -2.00 | -3.03 | -0.80 | -1.25 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 24.6M | 35.3M | 41.3M | 57.6M | 81.7M | 88.8M | 88.8M |
| Valuation | |||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | -25.3 |
| P/FCF | 5.7 | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 1.6 | 2.7 | 2.1 | N/A | 1.9 | N/A | 2.8 |
| Price/Sales | 12.9 | 27.1 | 11.4 | N/A | N/A | N/A | 13.1 |
| FCF Yield | 17.5% | -7.2% | -12.6% | -5.7% | -12.2% | N/A | -2.6% |
| Market Cap | 315M | 813M | 722M | 2.1B | 2.1B | 0 | 2.9B |
| Avg. Price | 10.20 | 21.48 | 14.04 | 23.03 | 37.22 | 0.00 | 32.35 |
| Year-End Price | 12.78 | 23.05 | 17.47 | 35.83 | 25.16 | 0.00 | 32.35 |
IDEAYA Biosciences, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is -16.1%.
IDEAYA Biosciences, Inc. (IDYA) has a 5-year average return on invested capital (ROIC) of -18.2%. This is below average and may indicate limited pricing power.
IDEAYA Biosciences, Inc. (IDYA) has a market capitalization of $2.9B. It is classified as a mid-cap stock.
IDEAYA Biosciences, Inc. (IDYA) does not currently pay a regular dividend.
IDEAYA Biosciences, Inc. (IDYA) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
IDEAYA Biosciences, Inc. (IDYA) reported annual revenue of $219 million in its most recent fiscal year, based on SEC EDGAR filings.
IDEAYA Biosciences, Inc. (IDYA) has a net profit margin of -52.0%. The company is currently unprofitable.
IDEAYA Biosciences, Inc. (IDYA) generated $-73 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
IDEAYA Biosciences, Inc. (IDYA) has a debt-to-equity ratio of 0.03. This indicates a conservatively financed balance sheet.
IDEAYA Biosciences, Inc. (IDYA) reported earnings per share (EPS) of $-1.28 in its most recent fiscal year.
IDEAYA Biosciences, Inc. (IDYA) has a return on equity (ROE) of -10.9%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 6 years of financial data for IDEAYA Biosciences, Inc. (IDYA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
IDEAYA Biosciences, Inc. (IDYA) has a book value per share of $11.52, based on its most recent annual SEC filing.